Pancreatic Cancer Pipeline 2026: Drugs in Trials & Targets

Remission & chronicity

Spontaneous remission

Essentially zero; one of the highest cancer mortality rates; 5-year survival ~12% overall; only 15-20% have resectable disease at diagnosis

Best-intervention remission

Resectable: surgery (Whipple) + FOLFIRINOX adjuvant: 54.4 months median OS (PRODIGE 24, vs 35.0 months gemcitabine); BRCA-mutant metastatic: olaparib maintenance after platinum-based: 7.4 vs 3.8 months PFS (POLO); neoadjuvant chemotherapy: may convert 20-30% of borderline-resectable to resectable

Gap size

Very large — minimal survival improvement for most patients over past 20 years; imaging and liquid biopsy for early detection is the biggest opportunity

Primary barrier

biological + access (early detection)

Pancreatic cancer is detected late (70-80% at Stage III-IV) due to absence of early symptoms and screening; CA19-9 is insufficiently sensitive/specific for early detection; BRCA1/2 and other HRR mutation testing is not universal; KRAS G12D/G12V targeted agents represent a genuine pipeline advance

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

BRCA1 283 BRCA2 19 CDKN2A 29 CLDN18 2 EGFR 403 KRAS 233 NTRK1 256 PALB2 4 PARP1 207 SMAD4 5 TOP1 297 TP53 652 TYMS 170

BRCA1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
7-HYDROXY ISOFLAVONE	? unclear	Mechanistic	DGIdb
OLAPARIB	? unclear	Mechanistic	DGIdb
PLATINUM COMPOUND	? unclear	Mechanistic	DGIdb
DAIDZIN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL581929	? unclear	Mechanistic	DGIdb
PIDNARULEX	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1481721	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL484663	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1214407	? unclear	Mechanistic	DGIdb
2-PHENYLQUINOLINE	? unclear	Mechanistic	DGIdb
HARMALOL	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1574420	? unclear	Mechanistic	DGIdb
DOXORUBICIN HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
MITOMYCIN	? unclear	Mechanistic	DGIdb
PACLITAXEL PROTEIN-BOUND	? unclear	Mechanistic	DGIdb
RESVERATROL	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL12658	? unclear	Mechanistic	DGIdb
ONONIN	? unclear	Mechanistic	DGIdb
CEDIRANIB	? unclear	Mechanistic	DGIdb
PIPERINE	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL446567	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL546649	? unclear	Mechanistic	DGIdb
DEPHOSTATIN	? unclear	Mechanistic	DGIdb
SEMUSTINE	? unclear	Mechanistic	DGIdb
CISPLATIN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1404865	? unclear	Mechanistic	DGIdb
QUARFLOXIN	? unclear	Mechanistic	DGIdb
PARP/TANKYRASE INHIBITOR 2X-121	? unclear	Mechanistic	DGIdb
WISTIN	? unclear	Mechanistic	DGIdb
CHRYSIN DIMETHYL ETHER	? unclear	Mechanistic	DGIdb
GEMCITABINE	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL600315	? unclear	Mechanistic	DGIdb
AURINTRICARBOXYLIC ACID	? unclear	Mechanistic	DGIdb
MITOXANTRONE HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
SACITUZUMAB GOVITECAN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL588683	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL593254	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL588525	? unclear	Mechanistic	DGIdb
PURPURIN	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL316796	? unclear	Mechanistic	DGIdb

Showing top 40 of 283 agents ranked by evidence tier.

BRCA2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
CARBOPLATIN	? unclear	Mechanistic	DGIdb
OLAPARIB	? unclear	Mechanistic	DGIdb
TALAZOPARIB	? unclear	Mechanistic	DGIdb
NIRAPARIB	? unclear	Mechanistic	DGIdb
RUCAPARIB	? unclear	Mechanistic	DGIdb
QUARFLOXIN	? unclear	Mechanistic	DGIdb
CISPLATIN	? unclear	Mechanistic	DGIdb
VELIPARIB	? unclear	Mechanistic	DGIdb
BOSUTINIB	? unclear	Mechanistic	DGIdb
PLATINUM COMPOUND	? unclear	Mechanistic	DGIdb
TEMOZOLOMIDE	? unclear	Mechanistic	DGIdb
ENZALUTAMIDE	? unclear	Mechanistic	DGIdb
DASATINIB ANHYDROUS	? unclear	Mechanistic	DGIdb
GEMCITABINE	? unclear	Mechanistic	DGIdb
PIDNARULEX	? unclear	Mechanistic	DGIdb
SACITUZUMAB GOVITECAN	? unclear	Mechanistic	DGIdb
CEDIRANIB	? unclear	Mechanistic	DGIdb
INIPARIB	? unclear	Mechanistic	DGIdb
PARP/TANKYRASE INHIBITOR 2X-121	? unclear	Mechanistic	DGIdb

CDKN2A

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
(10R)-10-METHYL-3-(6-METHYLPYRIDIN-3-YL)-9,10,11,12-TETRAHYDRO-8H-[1,4]DIAZEPINO[5',6':4,5]THIENO[3,2-F]QUINOLIN-8-ONE	? unclear	Mechanistic	DGIdb
LETROZOLE	? unclear	Mechanistic	DGIdb
PALBOCICLIB	? unclear	Mechanistic	DGIdb
VEMURAFENIB	? unclear	Mechanistic	DGIdb
PF-04691502	? unclear	Mechanistic	DGIdb
SIROLIMUS	? unclear	Mechanistic	DGIdb
CARBOPLATIN	? unclear	Mechanistic	DGIdb
TEMOZOLOMIDE	? unclear	Mechanistic	DGIdb
DABRAFENIB	? unclear	Mechanistic	DGIdb
ABEMACICLIB	? unclear	Mechanistic	DGIdb
POLO-LIKE KINASE 1 INHIBITOR GSK461364	? unclear	Mechanistic	DGIdb
PACLITAXEL PROTEIN-BOUND	? unclear	Mechanistic	DGIdb
CETUXIMAB	? unclear	Mechanistic	DGIdb
IMMUNE CHECKPOINT INHIBITOR	? unclear	Mechanistic	DGIdb
COBIMETINIB	? unclear	Mechanistic	DGIdb
ULIXERTINIB	? unclear	Mechanistic	DGIdb
SAPANISERTIB	? unclear	Mechanistic	DGIdb
ALVOCIDIB	? unclear	Mechanistic	DGIdb
MILCICLIB	? unclear	Mechanistic	DGIdb
HMN-214	? unclear	Mechanistic	DGIdb
TRAMETINIB DIMETHYL SULFOXIDE	? unclear	Mechanistic	DGIdb
RIBOCICLIB	? unclear	Mechanistic	DGIdb
GEMCITABINE	? unclear	Mechanistic	DGIdb
ILORASERTIB	? unclear	Mechanistic	DGIdb
RONICICLIB	? unclear	Mechanistic	DGIdb
PF-00477736	? unclear	Mechanistic	DGIdb
PANITUMUMAB	? unclear	Mechanistic	DGIdb
BUPARLISIB	? unclear	Mechanistic	DGIdb
EVEROLIMUS	? unclear	Mechanistic	DGIdb

CLDN18

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
ZOLBETUXIMAB	? unclear	Mechanistic		DGIdb
ZWB67	? unclear	Mechanistic		DGIdb

EGFR

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
AUMOLERTINIB	↓ inhibits	Mechanistic		DGIdb
AFATINIB	↓ inhibits	Mechanistic		DGIdb
ABIVERTINIB	↓ inhibits	Mechanistic		DGIdb
FUTUXIMAB	↓ inhibits	Mechanistic		DGIdb
RINDOPEPIMUT	? unclear	Mechanistic		DGIdb
PD-0166285 HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
CISPLATIN	? unclear	Mechanistic		DGIdb
OLMUTINIB	↓ inhibits	Mechanistic		DGIdb
OSIMERTINIB MESYLATE	↓ inhibits	Mechanistic		DGIdb
ABIVERTINIB MALEATE	↓ inhibits	Mechanistic		DGIdb
ROCILETINIB	↓ inhibits	Mechanistic		DGIdb
GEFITINIB	↓ inhibits	Mechanistic	515.0 nM (IC50)	DGIdb
MATUZUMAB	↓ inhibits	Mechanistic		DGIdb
GRACILIN J	? unclear	Mechanistic		DGIdb
NIMOTUZUMAB	↓ inhibits	Mechanistic		DGIdb
LAZERTINIB	↓ inhibits	Mechanistic		DGIdb
LAPATINIB	↓ inhibits	Mechanistic		DGIdb
PANITUMUMAB	↓ inhibits	Mechanistic		DGIdb
DOSIMERTINIB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 17B [PMID: 35286086]	↓ inhibits	Mechanistic		DGIdb
IBRUTINIB	↓ inhibits	Mechanistic		DGIdb
POZIOTINIB	↓ inhibits	Mechanistic		DGIdb
TARLOXOTINIB	↓ inhibits	Mechanistic		DGIdb
OSIMERTINIB	↓ inhibits	Mechanistic		DGIdb
DACOMITINIB ANHYDROUS	↓ inhibits	Mechanistic		DGIdb
ICOTINIB HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
MIFANERTINIB	↓ inhibits	Mechanistic		DGIdb
NAQUOTINIB	↓ inhibits	Mechanistic		DGIdb
BMS-690514	↓ inhibits	Mechanistic		DGIdb
NAZARTINIB	↓ inhibits	Mechanistic		DGIdb
CUDC-101	↓ inhibits	Mechanistic		DGIdb
DEHYDRATED ALCOHOL	? unclear	Mechanistic		DGIdb
BEFOTERTINIB	↓ inhibits	Mechanistic		DGIdb
NECITUMUMAB	↓ inhibits	Mechanistic		DGIdb
CHEMBL:CHEMBL1914653	? unclear	Mechanistic		DGIdb
LAPRITUXIMAB EMTANSINE	? unclear	Mechanistic		DGIdb
INDIUM-111	? unclear	Mechanistic		DGIdb
AV-412	↓ inhibits	Mechanistic		DGIdb
CETUXIMAB	↓ inhibits	Mechanistic		DGIdb
EPIREGULIN	? unclear	Mechanistic		DGIdb

Showing top 40 of 403 agents ranked by evidence tier.

KRAS

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
GEMCITABINE	? unclear	Mechanistic		DGIdb
VEDROPREVIR	↓ inhibits	Mechanistic		DGIdb
COBIMETINIB	? unclear	Mechanistic		DGIdb
BEVACIZUMAB	? unclear	Mechanistic		DGIdb
RAS PEPTIDE CANCER VACCINE	? unclear	Mechanistic		DGIdb
PACLITAXEL PROTEIN-BOUND	? unclear	Mechanistic		DGIdb
SOTORASIB	? unclear	Mechanistic	68.0 nM (IC50)	DGIdb
AMG410	~ modulates	Mechanistic		DGIdb
NIVOLUMAB	? unclear	Mechanistic		DGIdb
PIMASERTIB	? unclear	Mechanistic		DGIdb
METFORMIN	? unclear	Mechanistic		DGIdb
TIZATERKIB	? unclear	Mechanistic		DGIdb
GARSORASIB	↓ inhibits	Mechanistic		DGIdb
CAPECITABINE	? unclear	Mechanistic		DGIdb
ENCORAFENIB	? unclear	Mechanistic		DGIdb
DACTOLISIB	? unclear	Mechanistic		DGIdb
IRINOTECAN HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
PICTILISIB	? unclear	Mechanistic		DGIdb
PEMBROLIZUMAB	? unclear	Mechanistic		DGIdb
ARS-1620	↓ inhibits	Mechanistic		DGIdb
DASATINIB ANHYDROUS	? unclear	Mechanistic		DGIdb
COMPOUND 25 [PMID: 32023060]	↓ inhibits	Mechanistic		DGIdb
DANOPREVIR	↓ inhibits	Mechanistic		DGIdb
DOCETAXEL ANHYDROUS	? unclear	Mechanistic		DGIdb
MUC1-TARGETED PEPTIDE GO-203-2C	? unclear	Mechanistic		DGIdb
THERAPEUTIC TUMOR INFILTRATING LYMPHOCYTES	? unclear	Mechanistic		DGIdb
AZACITIDINE	? unclear	Mechanistic		DGIdb
B-RAF/VEGFR-2 INHIBITOR RAF265	? unclear	Mechanistic		DGIdb
PARITAPREVIR	↓ inhibits	Mechanistic		DGIdb
VANIPREVIR	↓ inhibits	Mechanistic		DGIdb
DUAL IGF-1R/INSR INHIBITOR BMS-754807	? unclear	Mechanistic		DGIdb
SORAFENIB	? unclear	Mechanistic		DGIdb
CILUPREVIR	↓ inhibits	Mechanistic		DGIdb
TRASTUZUMAB	? unclear	Mechanistic		DGIdb
TEMSIROLIMUS	? unclear	Mechanistic		DGIdb
DECITABINE	? unclear	Mechanistic		DGIdb
SALIRASIB	↓ inhibits	Mechanistic		DGIdb
PHA-665752	? unclear	Mechanistic		DGIdb
MITOGEN-ACTIVATED PROTEIN KINASE KINASE INHIBITOR	? unclear	Mechanistic		DGIdb
SELUMETINIB	↓ inhibits	Mechanistic		DGIdb

Showing top 40 of 233 agents ranked by evidence tier.

NTRK1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
THERAPEUTIC CYTOKINE	? unclear	Mechanistic		DGIdb
ENTRECTINIB	↓ inhibits	Mechanistic		DGIdb
MK-2461	↓ inhibits	Mechanistic		DGIdb
GW843682X	? unclear	Mechanistic		DGIdb
ESTRADIOL VALERATE	? unclear	Mechanistic		DGIdb
CH7057288	↓ inhibits	Mechanistic		DGIdb
LAROTRECTINIB	↓ inhibits	Mechanistic		DGIdb
GAMBOGIC ACID	? unclear	Mechanistic		DGIdb
PEGCANTRATINIB	? unclear	Mechanistic		DGIdb
WORTMANNIN	? unclear	Mechanistic		DGIdb
D5261	~ modulates	Mechanistic		DGIdb
METHOTREXATE	? unclear	Mechanistic		DGIdb
UTATRECTINIB	↓ inhibits	Mechanistic		DGIdb
DOVITINIB	↓ inhibits	Mechanistic	100.0 nM (Kd)	DGIdb
TALETRECTINIB	↓ inhibits	Mechanistic		DGIdb
CEP-2563 DIHYDROCHLORIDE	? unclear	Mechanistic		DGIdb
GAMBOGIC AMIDE	? unclear	Mechanistic		DGIdb
SP-600125	? unclear	Mechanistic		DGIdb
GAMMA-INTERFERON	? unclear	Mechanistic		DGIdb
MILCICLIB	↓ inhibits	Mechanistic	53.0 nM (IC50)	DGIdb
PHENYLEPHRINE HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
JNJ-28312141	↓ inhibits	Mechanistic		DGIdb
DZX19	↓ inhibits	Mechanistic		DGIdb
CYCLOPHOSPHAMIDE ANHYDROUS	? unclear	Mechanistic		DGIdb
SITRAVATINIB	↓ inhibits	Mechanistic		DGIdb
ONO-7579	? unclear	Mechanistic		DGIdb
IMATINIB	? unclear	Mechanistic		DGIdb
ALISERTIB	? unclear	Mechanistic		DGIdb
CYTARABINE	? unclear	Mechanistic		DGIdb
REPOTRECTINIB	↓ inhibits	Mechanistic		DGIdb
ZIDESAMTINIB	↓ inhibits	Mechanistic		DGIdb
SURAMIN	? unclear	Mechanistic		DGIdb
PLX7486	? unclear	Mechanistic		DGIdb
AZD-6918	↓ inhibits	Mechanistic		DGIdb
ASPIRIN	? unclear	Mechanistic		DGIdb
CZS-241	↓ inhibits	Mechanistic		DGIdb
RADICICOL	? unclear	Mechanistic		DGIdb
LEVOTHYROXINE SODIUM	? unclear	Mechanistic		DGIdb
LESTAURTINIB	↓ inhibits	Mechanistic		DGIdb
PILOCARPINE HYDROCHLORIDE	? unclear	Mechanistic		DGIdb

Showing top 40 of 256 agents ranked by evidence tier.

PALB2

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
TALAZOPARIB	? unclear	Mechanistic	DGIdb
OLAPARIB	? unclear	Mechanistic	DGIdb
MITOMYCIN	? unclear	Mechanistic	DGIdb
RUCAPARIB	? unclear	Mechanistic	DGIdb

PARP1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
NIRAPARIB	↓ inhibits	Mechanistic	DGIdb
VELIPARIB	↓ inhibits	Mechanistic	DGIdb
4-[3-(1,4-DIAZEPAN-1-YLCARBONYL)-4-FLUOROBENZYL]PHTHALAZIN-1(2H)-ONE	↓ inhibits	Mechanistic	DGIdb
PAMIPARIB	↓ inhibits	Mechanistic	DGIdb
OLAPARIB	↓ inhibits	Mechanistic	DGIdb
COMPOUND 5 [TOMASSI ET AL., 2020]	↓ inhibits	Mechanistic	DGIdb
COMPOUND 9 [LIN ET AL., 2023]	↓ inhibits	Mechanistic	DGIdb
INIPARIB	↓ inhibits	Mechanistic	DGIdb
AZ1366	↓ inhibits	Mechanistic	DGIdb
DUAL VEGFR/PARP INHIBITOR 14B	↓ inhibits	Mechanistic	DGIdb
NIACIN	? unclear	Mechanistic	DGIdb
2X-121	↓ inhibits	Mechanistic	DGIdb
AMELPARIB DIHYDROCHLORIDE DIHYDRATE	↓ inhibits	Mechanistic	DGIdb
CEP-9722	? unclear	Mechanistic	DGIdb
ORAL AZACITIDINE	? unclear	Mechanistic	DGIdb
RUCAPARIB PHOSPHATE	↓ inhibits	Mechanistic	DGIdb
AG14361	↓ inhibits	Mechanistic	DGIdb
ME0328	↓ inhibits	Mechanistic	DGIdb
SARUPARIB	↓ inhibits	Mechanistic	DGIdb
SENAPARIB	↓ inhibits	Mechanistic	DGIdb
NIRAPARIB TOSYLATE	? unclear	Mechanistic	DGIdb
TALAZOPARIB	↓ inhibits	Mechanistic	DGIdb
PJ34	↓ inhibits	Mechanistic	DGIdb
TALAZOPARIB TOSYLATE	↓ inhibits	Mechanistic	DGIdb
PARP1 INHIBITOR (S)-G9	↓ inhibits	Mechanistic	DGIdb
NICARAVEN	? unclear	Mechanistic	DGIdb
PARP-1/2 INHIBITOR ABT-767	? unclear	Mechanistic	DGIdb
INO-1001	? unclear	Mechanistic	DGIdb
BGP-15	? unclear	Mechanistic	DGIdb
RUCAPARIB	↓ inhibits	Mechanistic	DGIdb
TRABECTEDIN	? unclear	Mechanistic	DGIdb
VENADAPARIB	↓ inhibits	Mechanistic	DGIdb
FLUZOPARIB	↓ inhibits	Mechanistic	DGIdb
MC2050	↓ inhibits	Mechanistic	DGIdb
PARP INHIBITOR E7016	? unclear	Mechanistic	DGIdb
LERZEPARIB	↓ inhibits	Mechanistic	DGIdb
CICLOPIROX	↓ inhibits	Mechanistic	DGIdb
E-7016	↓ inhibits	Mechanistic	DGIdb
RUCAPARIB CAMSYLATE	↓ inhibits	Mechanistic	DGIdb
PALACAPARIB	↓ inhibits	Mechanistic	DGIdb

Showing top 40 of 207 agents ranked by evidence tier.

SMAD4

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
LYSINE	? unclear	Mechanistic	DGIdb
FLUOROURACIL	? unclear	Mechanistic	DGIdb
CETUXIMAB	? unclear	Mechanistic	DGIdb
RECOMBINANT TRANSFORMING GROWTH FACTOR	? unclear	Mechanistic	DGIdb
GEMCITABINE	? unclear	Mechanistic	DGIdb

TOP1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
9-AMINOCAMPTOTHECIN	↓ inhibits	Mechanistic	4200.0 nM (IC50)	DGIdb
BELOTECAN	↓ inhibits	Mechanistic		DGIdb
LIPOSOMAL SN-38	? unclear	Mechanistic		DGIdb
TRYPTANTHRIN	? unclear	Mechanistic		DGIdb
INTOPLICINE	? unclear	Mechanistic		DGIdb
INDIMITECAN	? unclear	Mechanistic		DGIdb
AESCULIOSIDE IVC	? unclear	Mechanistic		DGIdb
CHEMBL:CHEMBL1094675	? unclear	Mechanistic		DGIdb
INDOTECAN	? unclear	Mechanistic		DGIdb
DATOPOTAMAB DERUXTECAN	↓ inhibits	Mechanistic		DGIdb
ETIRINOTECAN PEGOL	↓ inhibits	Mechanistic		DGIdb
MANSONONE F	? unclear	Mechanistic		DGIdb
EXATECAN	↓ inhibits	Mechanistic		DGIdb
(20S,21S)-FLUOROCAMPTOTHECIN	? unclear	Mechanistic		DGIdb
AFELETECAN	~ modulates	Mechanistic		DGIdb
CAMPTOTHECIN	↓ inhibits	Mechanistic	700.0 nM (IC50)	DGIdb
CHEMBL:CHEMBL2171793	? unclear	Mechanistic		DGIdb
LABETUZUMAB GOVITECAN	↓ inhibits	Mechanistic		DGIdb
TLC-388	↓ inhibits	Mechanistic		DGIdb
OLIVOMYCIN I	? unclear	Mechanistic		DGIdb
AESCULIOSIDE IIID	? unclear	Mechanistic		DGIdb
IRINOTECAN HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
LURTOTECAN	? unclear	Mechanistic		DGIdb
CAFFEINE	? unclear	Mechanistic		DGIdb
EDOTECARIN	? unclear	Mechanistic	51.0 nM (EC50)	DGIdb
PEGAMOTECAN	? unclear	Mechanistic		DGIdb
TAFLUPOSIDE	? unclear	Mechanistic		DGIdb
AESCULIOSIDE IIIB	? unclear	Mechanistic		DGIdb
KARENITECIN	↓ inhibits	Mechanistic		DGIdb
AESCULIOSIDE IIIF	? unclear	Mechanistic		DGIdb
CALOTHRIXIN A	? unclear	Mechanistic		DGIdb
CHEMBL:CHEMBL308106	? unclear	Mechanistic		DGIdb
AESCULIOSIDE IIIA	? unclear	Mechanistic		DGIdb
BROMOETHANE	? unclear	Mechanistic		DGIdb
PLUKENETIONE A	? unclear	Mechanistic		DGIdb
TOPOISOMERASE INHIBITOR	? unclear	Mechanistic		DGIdb
DRF-1042	? unclear	Mechanistic		DGIdb
FIRTECAN PEGOL	? unclear	Mechanistic		DGIdb
LIPOTECAN	? unclear	Mechanistic		DGIdb
(S)-DRF-1042	↓ inhibits	Mechanistic		DGIdb

Showing top 40 of 297 agents ranked by evidence tier.

TP53

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
PIRARUBICIN	? unclear	Mechanistic	DGIdb
OXALIPLATIN	? unclear	Mechanistic	DGIdb
SIREMADLIN	↓ inhibits	Mechanistic	DGIdb
CARBOPLATIN	? unclear	Mechanistic	DGIdb
DAUNORUBICIN HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL260560	? unclear	Mechanistic	DGIdb
MELPHALAN	? unclear	Mechanistic	DGIdb
LAPACHONE	? unclear	Mechanistic	DGIdb
VITAMIN K3	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL260451	? unclear	Mechanistic	DGIdb
DINOSEB	? unclear	Mechanistic	DGIdb
RIMCAZOLE	? unclear	Mechanistic	DGIdb
TRACAZOLATE	? unclear	Mechanistic	DGIdb
CAPIVASERTIB	? unclear	Mechanistic	DGIdb
AZD7648	? unclear	Mechanistic	DGIdb
QUINALIZARIN	? unclear	Mechanistic	DGIdb
INOSITOL	? unclear	Mechanistic	DGIdb
ECONAZOLE NITRATE	? unclear	Mechanistic	DGIdb
L-733,060	? unclear	Mechanistic	DGIdb
U50488	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL260028	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL601140	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL408563	? unclear	Mechanistic	DGIdb
ENALAPRIL MALEATE	? unclear	Mechanistic	DGIdb
HOMIDIUM BROMIDE	? unclear	Mechanistic	DGIdb
IOXYNIL	? unclear	Mechanistic	DGIdb
ACALABRUTINIB	? unclear	Mechanistic	DGIdb
INDOPROFEN	? unclear	Mechanistic	DGIdb
MERCAPTOPURINE	? unclear	Mechanistic	DGIdb
AUTOLOGOUS DENDRITIC CELLS TRANSDUCED WITH WILD-TYPE P53 ADENOVIRUS VACCINE	? unclear	Mechanistic	DGIdb
ZIRAM	? unclear	Mechanistic	DGIdb
IFOSFAMIDE	? unclear	Mechanistic	DGIdb
DOCETAXEL ANHYDROUS	? unclear	Mechanistic	DGIdb
SOTULETINIB	? unclear	Mechanistic	DGIdb
SERTRALINE HYDROCHLORIDE	? unclear	Mechanistic	DGIdb
PD166285	? unclear	Mechanistic	DGIdb
SAPANISERTIB	? unclear	Mechanistic	DGIdb
ENZALUTAMIDE	? unclear	Mechanistic	DGIdb
PYRITHIONE ZINC	? unclear	Mechanistic	DGIdb
CHEMBL:CHEMBL1169388	? unclear	Mechanistic	DGIdb

Showing top 40 of 652 agents ranked by evidence tier.

TYMS

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
FLUOROURACIL	↓ inhibits	Mechanistic		DGIdb
PREDNISONE	? unclear	Mechanistic		DGIdb
TAMOXIFEN CITRATE	? unclear	Mechanistic		DGIdb
PEMETREXED DISODIUM	↓ inhibits	Mechanistic		DGIdb
CAPECITABINE	↓ inhibits	Mechanistic		DGIdb
OSI-7904L	? unclear	Mechanistic		DGIdb
AZATHIOPRINE	? unclear	Mechanistic		DGIdb
FOLIC ACID	? unclear	Mechanistic		DGIdb
RISPERIDONE	? unclear	Mechanistic		DGIdb
OSI-7904	↓ inhibits	Mechanistic	0.09 nM (Ki)	DGIdb
MITOMYCIN	? unclear	Mechanistic		DGIdb
AMINOCAMPTOTHECIN	? unclear	Mechanistic		DGIdb
DEOXYURIDINE MONOPHOSPHATE	? unclear	Mechanistic		DGIdb
RESERPINE	? unclear	Mechanistic		DGIdb
HYDROXYCHLOROQUINE	? unclear	Mechanistic		DGIdb
INDOMETHACIN	? unclear	Mechanistic		DGIdb
DAUNORUBICIN HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
ETOPOSIDE	? unclear	Mechanistic		DGIdb
DEXAMETHASONE	? unclear	Mechanistic		DGIdb
5-FLUOROURACIL/SALICYLIC ACID TOPICAL SOLUTION	? unclear	Mechanistic		DGIdb
NOLATREXED	↓ inhibits	Mechanistic		DGIdb
IRINOTECAN HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
LEUCOVORIN CALCIUM	? unclear	Mechanistic		DGIdb
DOXIFLURIDINE	↓ inhibits	Mechanistic		DGIdb
CARBOGEN	? unclear	Mechanistic		DGIdb
ARFOLITIXORIN	? unclear	Mechanistic		DGIdb
HYDROCORTISONE BUTYRATE	? unclear	Mechanistic		DGIdb
METHOTREXATE	? unclear	Mechanistic	3600.0 nM (IC50)	DGIdb
AZACITIDINE	? unclear	Mechanistic		DGIdb
FOLATE ANTAGONIST	? unclear	Mechanistic		DGIdb
GAMMA-INTERFERON	? unclear	Mechanistic		DGIdb
CISPLATIN	? unclear	Mechanistic		DGIdb
ENILURACIL	? unclear	Mechanistic		DGIdb
THYMIDINE MONOPHOSPHATE	? unclear	Mechanistic		DGIdb
IDETREXED	? unclear	Mechanistic		DGIdb
VINCRISTINE	? unclear	Mechanistic		DGIdb
PLATINUM	? unclear	Mechanistic		DGIdb
TEGAFUR	↓ inhibits	Mechanistic		DGIdb
VERAPAMIL	? unclear	Mechanistic		DGIdb
RALTITREXED	↓ inhibits	Mechanistic	880.0 nM (IC50)	DGIdb

Showing top 40 of 170 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Pancreatic Cancer: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer Recruiting

NCT07671339 Phase: 1 Started: 2026-06-22

The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find o...

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer Recruiting

NCT07756281 Phase: 1 Started: 2026-09-01

This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerab...

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer Recruiting

NCT07895498 Phase: 2 Started: 2026-10-16

The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (dara...

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Recruiting

NCT02830724 Phase: 1/2 Started: 2017-04-06

Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the...

An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors Recruiting

NCT07806058 Phase: 1/2 Started: 2026-10-15

This is a Phase IB/II clinical trial designed to evaluate HRS-7172 in combination with antitumor drugs in participants with advanced pancreatic cancer harboring RAS mutations or amplifications. The study process includes a screening period (from signed informed consent to first dose), a treatment pe...

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer Recruiting

NCT07232875 Phase: 3 Started: 2025-11-21

This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting

NCT07562152 Phase: 3 Started: 2026-06-05

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy Recruiting

NCT07892573 Phase: N/A Started: 2026-10-07

This is a prospective, single-arm, single-center exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of a triplet regimen-becotatug vedotin combined with anti-PD-1 and S-1-in patients with EGFR-positive advanced pancreatic cancer who have failed at least one ...

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting

NCT07252232 Phase: 3 Started: 2025-12-15

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer Recruiting

NCT07444541 Phase: 1/2 Started: 2026-12

The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer Completed

NCT05908747 Phase: 2 Started: 2023-05-31

This study is designed to explore the efficacy and safety of surufatinib combined with gemcitabine and nab-paclitaxel as peri-operative treatment in locally advanced or borderline resectable pancreatic cancer.

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer Recruiting

NCT05911217 Phase: 1 Started: 2023-07-11

An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer Completed

NCT04820179 Phase: 2 Started: 2021-10-12

Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease. Combination treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has sho...

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma Recruiting

NCT07805954 Phase: 3 Started: 2026-08-28

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer Active Not Recruiting

NCT03816163 Phase: 2 Started: 2019-03-15

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to atta...

Agents Found By Disease-Level Search

Searched directly from “Pancreatic Cancer” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 13-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

48 agents shown (approved or with trial evidence) — 39 not found by the gene-target search above.

Gemcitabine

Phase 3 · 8 trials · source: ClinicalTrials.gov, Open Targets
NCT04616534 NCT01020006 NCT00102752

Gemcitabine HydrochlorideNOT in gene-target list

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT02562716 NCT01770132 NCT00028834

Pembrolizumab

Phase 2 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT02432963 NCT04887805 NCT02907099

pancreaticoduodenectomyNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT04823832 NCT04596865 NCT07182136

Irinotecan Hydrochloride

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02562716 NCT00042939

Oxaliplatin

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02562716 NCT02035072

PancreatectomyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02562716 NCT07396662

bevacizumab

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00028834 NCT00614653

mFOLFIRINOXNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07671339 NCT04228601

sorafenib tosylateNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00131911 NCT00095966

gemcitabine + nab-paclitaxelNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07436741 NCT06182072

Nab-paclitaxelNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05031494 NCT07226856

capecitabine

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01824875 NCT00614653

OctreotideNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02381249 NCT00427349

Modified Vaccinia Virus Ankara Vaccine Expressing p53NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02432963

Defactinib

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07126158

Avutometinib

· 1 trial · source: ClinicalTrials.gov
NCT07126158

Akt Inhibitor MK2206NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01783171

DinaciclibNOT in gene-target list

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01783171

Fluorouracil

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02562716

Paclitaxel Albumin-Stabilized Nanoparticle FormulationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02562716

ElimusertibNOT in gene-target list

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04616534

porfimer sodiumNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01770132

endoscopic ultrasonographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01770132

photodynamic therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01770132

PCI-27483NOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01020006

SiltuximabNOT in gene-target list

Phase 1/2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04191421

SpartalizumabNOT in gene-target list

Phase 1/2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04191421

Gemcitabine fluorouracilNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04769414

BL-M17D1NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06500052

GlufosfamideNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00102752

HealthPatchNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02933307

ViSi MobileNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02933307

CM-24 and Nivolumab - Dose EscalationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04731467

CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - ExpansionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04731467

CM-24, Nivolumab, and Nal-IRI/5-FU/LV - ExpansionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04731467

Nivolumab, Nab paclitaxel and Gemcitabine - ExpansionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04731467

Nivolumab and Nal-IRI/5-FU/LV - ExpansionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04731467

Motor TestsNOT in gene-target list